HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

DYAI

Dyadic International Inc., DE

Last Close
Apr 25 • 04:00PM ET
1.18
Dollar change
-0.03
Percentage change
-2.48 		%
Healthcare • Biotechnology • USA • NASD
Peers: AMGN BIIB GILD VRTX REGN ILMN INCY NBIX NKTR EXEL
 | Held by: VTI VXF IWC
Scroll to Statements
Index- P/E- EPS (ttm)-0.20 Insider Own30.74% Shs Outstand29.84M Perf Week-4.07%
Market Cap35.51M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float20.84M Perf Month-11.28%
Income-5.81M PEG- EPS next Q- Inst Own16.92% Short Float0.81% Perf Quarter-19.73%
Sales3.50M P/S10.14 EPS this Y-15.00% Inst Trans10.54% Short Ratio4.04 Perf Half Y4.42%
Book/sh0.08 P/B14.25 EPS next Y0.00% ROA-64.01% Short Interest0.17M Perf Year-20.81%
Cash/sh0.31 P/C3.83 EPS next 5Y- ROE-139.16% 52W Range0.93 - 2.67 Perf YTD-32.57%
Dividend Est.- P/FCF- EPS past 5Y8.43% ROI-77.64% 52W High-55.81% Beta1.02
Dividend TTM- Quick Ratio4.01 Sales past 5Y17.35% Gross Margin65.82% 52W Low27.47% ATR (14)0.08
Dividend Ex-Date- Current Ratio4.01 EPS Y/Y TTM15.90% Oper. Margin-168.17% RSI (14)36.38 Volatility5.20% 5.99%
Employees6 Debt/Eq2.05 Sales Y/Y TTM20.58% Profit Margin-166.19% Recom1.00 Target Price9.00
Option/ShortYes / Yes LT Debt/Eq2.03 EPS Q/Q27.68% Payout- Rel Volume0.31 Prev Close1.21
Sales Surprise-49.04% EPS Surprise-25.00% Sales Q/Q19.06% EarningsMar 26 AMC Avg Volume41.56K Price1.18
SMA20-6.23% SMA50-13.46% SMA200-14.80% Trades Volume12,930 Change-2.48%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Downgrade Dawson James Buy → Neutral
Dec-17-21Initiated H.C. Wainwright Buy $7
Apr-16-25 02:00PM
Dyadic to Present at World Vaccine Congress Washington
(GlobeNewswire)
Mar-27-25 08:00AM
Q4 2024 Dyadic International Inc Earnings Call
(Thomson Reuters StreetEvents)
03:02AM
Dyadic International Inc (DYAI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
(GuruFocus.com)
Mar-26-25 10:58PM
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
(SeekingAlpha)
04:05PM
Dyadic Reports 2024 Year-End Financial Results and Business Updates
(GlobeNewswire)
09:04AM Loading…
Mar-25-25 09:04AM
What To Expect From Dyadic International Inc (DYAI) Q4 2024 Earnings
(GuruFocus.com)
Mar-20-25 08:30AM
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
(GlobeNewswire)
Mar-12-25 04:00PM
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
(GlobeNewswire)
Mar-06-25 08:30AM
Dyadic to Attend Multiple Industry Events in March
(GlobeNewswire)
Jan-06-25 08:30AM
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) +6.52%
Nov-21-24 08:30AM
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
(GlobeNewswire) +12.08%
Nov-13-24 02:21AM
Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
(GuruFocus.com)
Nov-12-24 04:05PM
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
(GlobeNewswire) +8.57%
Nov-11-24 07:27AM
Earnings To Watch: Dyadic International Inc (DYAI) Reports Q3 2024 Result
(GuruFocus.com) -7.89%
Nov-04-24 04:30PM
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
(GlobeNewswire)
06:19PM Loading…
Oct-09-24 06:19PM
Dyadic International Inc (DYAI) Q2 2024 Earnings Call Highlights: Strategic Positioning Amid ...
(GuruFocus.com)
08:00AM
Dyadic Expands Global Presence with Participation in Key Industry Events
(GlobeNewswire)
Sep-23-24 09:50AM
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
(GlobeNewswire)
Aug-13-24 04:05PM
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Jul-30-24 04:00PM
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
(GlobeNewswire)
Jun-28-24 08:30AM
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
(GlobeNewswire) -6.33%
May-30-24 04:30PM
Dyadic to Attend Industry Events in June
(GlobeNewswire) +5.58%
May-15-24 05:01PM
Dyadic International Inc (DYAI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review ...
(GuruFocus.com) +5.37% +5.73%
May-14-24 08:57PM
DYAI Stock Earnings: Dyadic International Reported Results for Q1 2024
(InvestorPlace)
04:00PM
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
May-08-24 08:30AM
Dyadic to Attend Industry and Investor Events in May
(GlobeNewswire)
Apr-30-24 04:30PM
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
(GlobeNewswire)
Apr-01-24 12:24PM
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-29-24 07:18AM
Q4 2023 Dyadic International Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-28-24 08:53PM
DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
04:00PM Loading…
04:00PM
Dyadic Reports 2023 Full Year Results and Recent Company Progress
(GlobeNewswire)
08:30AM
Dyadic Announces Change in Board and Management Leadership Roles
(GlobeNewswire)
Mar-27-24 08:30AM
Dyadic to Attend Industry Events in April
(GlobeNewswire)
Mar-26-24 08:30AM
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
(GlobeNewswire)
Mar-21-24 08:30AM
Dyadic to Attend Future Food Tech Event March 21 22, 2024 in San Francisco, California
(GlobeNewswire)
Mar-14-24 04:30PM
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
(GlobeNewswire) -5.00%
Mar-11-24 09:57AM
CORRECTION Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
(GlobeNewswire) +5.80%
08:30AM
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
(GlobeNewswire)
Mar-01-24 08:30AM
Dyadic to Attend Industry Events in March
(GlobeNewswire)
Feb-28-24 08:30AM
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
(GlobeNewswire)
Feb-23-24 02:00AM
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
(GlobeNewswire)
Feb-21-24 08:30AM
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
(GlobeNewswire) +11.85%
Feb-13-24 08:30AM
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
(GlobeNewswire)
Feb-06-24 08:30AM
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
(GlobeNewswire)
Feb-01-24 08:30AM
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
(GlobeNewswire) +6.15%
Jan-22-24 08:00AM
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
(Newsfile)
Jan-02-24 08:30AM
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
(GlobeNewswire)
Nov-30-23 08:30AM
Dyadic Attends Investor Events in December
(GlobeNewswire)
Nov-29-23 08:30AM
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
(GlobeNewswire)
Nov-20-23 08:30AM
Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
(GlobeNewswire) +5.85%
Nov-09-23 03:54PM
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-08-23 06:15PM
Dyadic International Inc (DYAI) Reports Decrease in Q3 Revenue and Net Loss Improvement ...
(GuruFocus.com)
04:00PM
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Oct-30-23 08:30AM
Dyadic to Present at Industry Events in November
(GlobeNewswire) +5.23%
Oct-25-23 04:30PM
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
(GlobeNewswire)
Oct-17-23 07:28AM
DYAI: Fall Update
(Zacks)
Oct-09-23 08:30AM
Dyadic Appoints Doug Pace to Its Executive Leadership Team
(GlobeNewswire)
Oct-05-23 08:30AM
Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ( VIC ) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
(GlobeNewswire)
Sep-29-23 08:30AM
Dyadic to Present at Industry and Investor Events in October
(GlobeNewswire)
Sep-26-23 08:30AM
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
(GlobeNewswire) -8.65%
Sep-19-23 08:00AM
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus
(GlobeNewswire)
Sep-12-23 04:30PM
Dyadic to Present at BioProcess International
(GlobeNewswire)
Aug-11-23 09:14AM
DYAI: MoUs Highlight C1 Vaccine Potential
(Zacks)
Aug-09-23 04:00PM
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
(GlobeNewswire) +10.00%
Aug-07-23 08:30AM
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
(GlobeNewswire)
Jul-26-23 04:30PM
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
(GlobeNewswire)
Jul-24-23 08:30AM
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
(GlobeNewswire)
Jun-21-23 08:33AM
Dyadic Announced an MoU with Bangladeshs State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
(GlobeNewswire)
Jun-01-23 08:30AM
Dyadic to Participate at Upcoming Events in June
(GlobeNewswire)
May-12-23 06:32AM
Dyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three years
(Simply Wall St.)
May-11-23 11:18AM
DYAI: Abundant Opportunities in Products and Animal & Human Health
(Zacks Small Cap Research) +10.47%
May-10-23 04:00PM
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
08:30AM
Dyadic to Participate at Two Industry Events in May
(GlobeNewswire)
May-08-23 08:30AM
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus
(GlobeNewswire) +5.93%
Apr-26-23 04:30PM
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
(GlobeNewswire) +16.02%
Apr-18-23 08:30AM
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
(GlobeNewswire) -9.92%
Apr-12-23 08:00AM
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
(GlobeNewswire)
Apr-01-23 12:47PM
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript
(Insider Monkey)
09:09AM
Dyadic International Full Year 2022 Earnings: Revenues Disappoint
(Simply Wall St.)
Mar-30-23 10:29AM
DYAI: 2022 Results
(Zacks Small Cap Research) +19.80%
08:30AM
Dyadic to Present at World Vaccine Congress Washington 2023
(GlobeNewswire)
Mar-29-23 04:00PM
Dyadic Reports 2022 Year End Results and Recent Company Progress
(GlobeNewswire)
Mar-15-23 08:30AM
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
(GlobeNewswire)
Mar-12-23 10:08AM
Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation
(Simply Wall St.)
Mar-07-23 08:30AM
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
(GlobeNewswire) +19.86%
Mar-01-23 08:30AM
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
(GlobeNewswire) +9.49%
Feb-02-23 08:30AM
Dyadic to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Jan-31-23 05:56AM
DYAI: First Patient Administered C1 Derived Vaccine
(Zacks Small Cap Research)
Jan-24-23 08:30AM
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
(GlobeNewswire)
Jan-19-23 08:30AM
Dyadic Announces Sale of Equity Interest in Alphazyme
(GlobeNewswire)
Jan-04-23 08:30AM
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
(GlobeNewswire)
Dec-14-22 08:30AM
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
(GlobeNewswire)
Nov-11-22 07:10AM
DYAI: DYAI-100 Phase I in the Spotlight
(Zacks Small Cap Research) -8.70%
Nov-10-22 04:00PM
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
(GlobeNewswire)
Nov-07-22 08:30AM
Dyadic to Present at Upcoming Industry and Investor Events in November
(GlobeNewswire)
Nov-04-22 10:33AM
Those who invested in Dyadic International (NASDAQ:DYAI) five years ago are up 63%
(Simply Wall St.) -6.03%
Oct-27-22 04:30PM
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
(GlobeNewswire)
09:04AM
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
(GlobeNewswire)
Oct-04-22 08:45AM
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
(GlobeNewswire) -7.81%
Sep-13-22 08:00AM
Dyadic Updates Market on Recent Scientific Achievements
(GlobeNewswire) -5.75%
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Francisco Trust under agreemenGreater than 10% holderMar 31 '25Proposed Sale1.41215,793304,269Mar 31 04:00 PM
Kaye JackDirectorMar 05 '25Option Exercise1.3330,00039,90087,166Mar 07 04:07 PM
HERBST SETHDirectorJan 06 '25Option Exercise0.9725,00024,250180,759Jan 08 05:19 PM
Francisco Trust under agreemenGreater than 10% holderDec 20 '24Proposed Sale1.91295,893563,676Dec 20 03:56 PM
Tarnok Michael P.DirectorNov 22 '24Option Exercise0.9725,00024,250246,672Nov 25 11:59 AM
Buckland BarryDirectorJun 11 '24Option Exercise1.5911,79318,75138,967Jun 13 09:26 PM
Tarnok Michael P.DirectorMay 21 '24Option Exercise1.3630,00040,800246,103May 23 03:42 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • theme settings • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.